{
  "schema_version": "pdp_json_v1",
  "peptide": {
    "canonical_name": "Bpc-157",
    "short_name": "BPC-157",
    "aliases": [
      "Body Protection Compound-157",
      "bpc",
      "bpc 157",
      "bpc157",
      "Pentadecapeptide BPC 157"
    ],
    "classification": {
      "category": "investigational_human",
      "needs_prescription": false,
      "notes": "Not approved for human therapeutic use by major regulators. Frequently sold as 'research use only' and used off-label in wellness/athletic contexts."
    },
    "status": {
      "category": "investigational_human",
      "jurisdiction": "GLOBAL",
      "last_reviewed": "2026-01-17",
      "human_use_note": "BPC-157 is not an approved human drug. Human evidence is limited and heterogeneous. Regulatory bodies and anti-doping organizations flag it as an unapproved substance with meaningful uncertainty and potential safety concerns."
    },
    "structure": {
      "sequence_oneletter": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "amino_acid_seq": "Pentadecapeptide (15 amino acids)",
      "molecular_formula": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
      "molecular_weight": null,
      "structure_image_url": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon."
    },
    "risk": {
      "current_score": 7,
      "likelihood": "possible",
      "evidence_grade": "human_observational",
      "developmental_risk": true,
      "unknowns_penalty": true,
      "rationale": "High uncertainty and unapproved status combined with common non-medical injectable use patterns increases consequence risk. FDA compounding safety concerns cite limited safety information for proposed routes and potential immunogenicity/impurity characterization issues. Human clinical evidence is limited and not definitive.",
      "severity": "high",
      "risk_score": 7
    },
    "sections": {
      "overview": [
        {
          "title": "What it is",
          "text": "BPC-157 is a synthetic 15-amino-acid peptide widely discussed in injury-recovery and GI contexts. Much of the optimistic literature comes from animal and cell models; human clinical evidence is limited and not definitive."
        },
        {
          "title": "What drives real-world risk",
          "text": "The practical risk is less about a well-characterized side-effect profile and more about product quality, contamination, and non-medical injection practices in an unregulated market."
        }
      ],
      "use_cases": [],
      "mechanism": [],
      "human_effects": [],
      "preclinical_effects": [],
      "hypothesized_effects": [],
      "time_dynamics": [],
      "risks": [],
      "contraindications": [],
      "monitoring": [],
      "observed_exposure_ranges": [
        {
          "route": "varies",
          "unit": "study-dependent",
          "min": null,
          "max": null,
          "frequency": "varies",
          "duration": "varies",
          "population_group": "general",
          "notes": "Descriptive only. This app does not provide protocols. Not instructions.",
          "evidence_refs": [
            "E1",
            "E2",
            "E4"
          ]
        }
      ],
      "developmental_risk_block": [
        {
          "title": "Developmental / Adolescent risk",
          "population_group": "adolescent",
          "confidence": "moderate",
          "evidence_grade": "unknown",
          "text": "Adolescents are still calibrating long-term repair, endocrine, and neurodevelopmental setpoints. For BPC-157, high uncertainty plus unregulated real-world use patterns increase consequence risk. Treat 'unknown' as part of risk in under-18 athletes.",
          "evidence_refs": [
            "E2",
            "E3"
          ]
        }
      ],
      "interaction_summary": [],
      "current_outlook_bullets": [
        "a synthetic pentadecapeptide discussed in injury recovery and GI contexts",
        "tendon and ligament recovery support",
        "soft tissue healing after overuse or injury",
        "return-to-training support during rehab",
        "joint comfort and mobility support",
        "interest in tissue repair pathways"
      ]
    },
    "evidence": [
      {
        "id": "E1",
        "title": "Emerging Use of BPC-157 in Orthopaedic Sports Medicine",
        "source_type": "pmc",
        "source_id": "PMC12313605",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/",
        "published_date": "2025-01-01",
        "evidence_grade": "human_observational",
        "notes": "Sports medicine review summarizing preclinical evidence and limited human reports; highlights evidence gaps.",
        "year": 2025
      },
      {
        "id": "E2",
        "title": "FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks (BPC-157 entry)",
        "source_type": "fda",
        "source_id": "fda_compounding_category2_bpc157",
        "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "regulatory_label",
        "notes": "FDA compounding safety note: limited safety-related information for proposed routes; immunogenicity and impurity characterization concerns."
      },
      {
        "id": "E3",
        "title": "USADA: BPC-157 is prohibited and unapproved",
        "source_type": "usada",
        "source_id": "usada_bpc157",
        "url": "https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/",
        "published_date": "Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.",
        "evidence_grade": "human_observational",
        "notes": "Anti-doping perspective noting unapproved status and uncertainty for athlete use."
      },
      {
        "id": "E4",
        "title": "ClinicalTrials.gov: Safety and pharmacokinetics trial for BPC-157 (registered; results not posted)",
        "source_type": "clinicaltrials",
        "source_id": "NCT02637284",
        "url": "https://clinicaltrials.gov/study/NCT02637284",
        "published_date": "2015-12-22",
        "evidence_grade": "human_interventional",
        "notes": "Registered Phase I safety/PK study; publicly available outcomes may be limited.",
        "year": 2015
      }
    ],
    "changelog": [
      {
        "date": "2026-01-17",
        "change_type": "initial_entry",
        "summary": "Initial canonical entry for BPC-157",
        "detail": "Added unapproved peptide entry with strong uncertainty framing; included FDA compounding safety note + sports medicine review + anti-doping context; flagged developmental risk due to high uncertainty and common youth athlete interest.",
        "evidence_refs": [
          "E1",
          "E2",
          "E3",
          "E4"
        ]
      }
    ],
    "meta": {
      "appears_in_blends": [
        "bpc-157-tb-500",
        "glow",
        "klow"
      ]
    },
    "topics": {
      "primary": [
        "topic_injury_healing"
      ]
    },
    "slug": "bpc-157"
  },
  "canonical_name": "Bpc-157",
  "interactions": {
    "drug_classes": [
      "anticoagulants-antiplatelets",
      "nsaids"
    ],
    "supplement_classes": [],
    "peptides": []
  },
  "practical": {
    "bottom_line": "BPC-157 is commonly discussed for tendon/ligament and gut irritation complaints, but the strongest supportive evidence is preclinical. The biggest real-world risk is unregulated sourcing and non-medical injection practices—not a well-defined clinical safety profile.",
    "benefits": [
      "Often discussed for soft-tissue recovery support (largely anecdotal)",
      "Frequently discussed for GI irritation/comfort (evidence mixed; human data limited)",
      "Sometimes discussed for return-to-training support during rehab (anecdotal)"
    ],
    "side_effects_common": [
      "Injection-site irritation (when injected)",
      "Headache or fatigue (reports vary)",
      "GI upset or appetite change (reports vary)"
    ],
    "side_effects_serious": [
      "Allergic reaction signs (hives, facial swelling, trouble breathing)",
      "Fever, severe redness, or drainage at injection site (possible infection/contamination)",
      "Chest pain or severe shortness of breath"
    ],
    "who_should_be_cautious": [
      "People on anticoagulants/antiplatelets or NSAIDs (interaction/bleeding-risk context should be clinician-reviewed)",
      "Autoimmune disease history or prior significant allergic reactions (uncertain immune effects)",
      "Pregnant or breastfeeding individuals",
      "Adolescents / competitive athletes (uncertainty + anti-doping rules)"
    ],
    "schema_version": "practical_block_v1"
  }
}
